Etopophos Side Effects
Generic Name: etoposide
Note: This page contains information about the side effects of etoposide. Some of the dosage forms included on this document may not apply to the brand name Etopophos.
Not all side effects for Etopophos may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to etoposide: oral capsule, oral capsule liquid filled
Other dosage forms:
In addition to its needed effects, some unwanted effects may be caused by etoposide (the active ingredient contained in Etopophos). In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking etoposide:More common
- Black, tarry stools
- bleeding gums
- blood in the urine or stools
- chest pain
- painful or difficult urination
- pale skin
- pinpoint red spots on the skin
- shortness of breath
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- swollen glands
- troubled breathing with exertion
- unusual bleeding or bruising
- unusual tiredness or weakness
- Blurred vision
- difficulty with swallowing
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- fast heartbeat
- feeling of warmth
- numbness or tingling in the fingers or toes
- pounding in the ears
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- redness of the face, neck, arms, and occasionally, upper chest
- skin rash
- slow or fast heartbeat
- tightness in the chest
- Bone pain
- Abdominal or stomach pain, severe
- blistering, peeling, or loosening of the skin
- cough or hoarseness
- dark urine
- difficult breathing
- joint or muscle pain
- loss of appetite
- lower back or side pain
- muscle tremors
- nausea or vomiting
- rapid, deep breathing
- red, irritated eyes
- red skin lesions, often with a purple center
- stomach cramps
- yellow eyes or skin
Some of the side effects that can occur with etoposide may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Hair loss or thinning of the hair
- swelling or inflammation of the mouth
- weight loss
- Bad, unusual, or unpleasant (after) taste
- change in taste
- cracked lips
- general feeling of discomfort or illness
- lack or loss of strength
- pain or burning in the throat
- sleepiness or unusual drowsiness
For Healthcare Professionals
Applies to etoposide: intravenous powder for injection, intravenous solution, oral capsule
Hematologic toxicity including leukopenia with WBC counts less than 1,000 WBC/mm3 (3% to 17%), or less than 4,000 WBC/mm3 (60% to 91%), thrombocytopenia with platelet counts less than 50,000 platelets/mm3 (1% to 20%), or less than 100,000 platelets/mm3 (22% to 41%), and anemia (up to 33%) have been reported.
Myelosuppression is dose related and dose limiting. Granulocyte nadirs occur 7 to 14 days after drug administration and usually recover within 20 days. Platelet nadirs occur 9 to 16 days after drug administration. Bone marrow recovery is usually complete by the 20th day. No cumulative toxicity has been reported. Fever and infection have been reported in patients with neutropenia.
Acute leukemia (with or without a preleukemic phase) has been reported rarely in patients treated with etoposide (the active ingredient contained in Etopophos) in combination with other antineoplastic agents.
Etoposide induced leukemia has features distinct from the syndrome of secondary leukemia associated with alkylating agents. The secondary leukemia that may occur in patients receiving etoposide features a shorter latency period; a predominance of monocytic or myelomonocytic features; and frequent cytogenic abnormalities involving 11q23.
In five single-agent studies of etoposide phosphate used in the treatment of a variety of tumor types, WHO grade III or IV leukopenia, and granulocytopenia were reported more frequently among elderly patients.
Elderly patients may also be more sensitive to myelosuppression.
In one study, six of seven patients treated with 60 mg/m2/day dosages for 5 days developed bone marrow suppression. Three of the six patients developed life-threatening leukopenia, two with sepsis, one of which ended in septic death.
The severity of nausea and vomiting is generally mild to moderate. This effect can be prevented by the use of oral phenothiazines in most cases, if necessary. Treatment discontinuation is required in approximately 1% of patients.
Elderly patients may be more sensitive to gastrointestinal effects.
Gastrointestinal side effects primarily including nausea and vomiting (31% to 43%) have been reported. Abdominal pain (up to 2%), anorexia (10% to 13%), diarrhea (1% to 13%), stomatitis (1% to 6%) and dysphagia have also been reported. Constipation has been reported infrequently. Gastrointestinal toxicities are slightly more frequent after oral administration than after intravenous infusion.
In one study of 5 day continuous infusion in 17 patients, 2 patients suffered myocardial infarction and one patient suffered congestive failure during treatment.
Cardiovascular side effects including transient hypotension following rapid intravenous administration (1% to 2%) has been reported. Transient hypertension, congestive heart failure, and arrhythmias have been reported rarely.
Hypersensitivity side effects including anaphylactic-like reactions characterized by chills, fever, tachycardia, bronchospasm, dyspnea and/or hypotension (0.7% to 2%) have been reported. Hypertension and/or flushing have also been reported. Facial/tongue swelling, coughing, diaphoresis, cyanosis, tightness in throat, laryngospasm, back pain and/or loss of consciousness have sometimes occurred in association with the above reactions. An apparent hypersensitivity-associated apnea has been reported rarely. At least one hypersensitivity-associated death has been reported. Rash, urticaria, and/or pruritus have infrequently been reported.
At investigational dosages, a generalized pruritic erythematous macropapular rash, consistent with perivasculitis, has been reported.
Dermatologic side effects including reversible alopecia (8% to 66%), sometimes progressing to total baldness, have been reported. Pruritus, phlebitis, hyperpigmentation and radiation recall dermatitis have been reported rarely.
In one study of 21 consecutive days of etoposide therapy, alopecia occurred in 11 of the 12 patients at risk for this toxicity (four had pre-existing alopecia, and two were inevaluable due to early death).
Elderly patients may be more sensitive to alopecia.
Hepatic toxicity (up to 3%) has generally been reported in patients receiving higher than recommended dosages. One report notes three cases of severe hepatocellular injury induced by standard dosages.
Other side effects including aftertaste, fever, dysphagia, transient cortical blindness, and optic neuritis have been reported infrequently. Although the drug is not considered to be vesicant, chemical phlebitis has been reported in association with etoposide (the active ingredient contained in Etopophos) infusion.
Metabolic acidosis has been reported in patients receiving higher than recommended dosages.
Respiratory side effects including a case report of fatal (biopsy-proven) pulmonary toxicity associated with the use of etoposide (the active ingredient contained in Etopophos) in a SCLC patient have been reported.
In five single-agent studies of etoposide (the active ingredient contained in Etopophos) phosphate used in the treatment of a variety of tumor types, asthenia was reported more frequently among elderly patients.
General side effects including asthenia have been reported.
Immunologic side effects including infectious complications have been reported.
Elderly patients may be more sensitive to infectious complications.
More about Etopophos (etoposide)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.